Anti-CC50B/ ™EM30B/ CDC50B monoclonal antibody

Anti-CC50B/ ™EM30B/ CDC50B antibody for FACS & in-vivo assay

Target products collectionGo to ™EM30B/™EM30B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1833-Ab-1/ GM-Tg-hg-MP1833-Ab-2Anti-Human ™EM30B monoclonal antibodyHuman
GM-Tg-rg-MP1833-Ab-1/ GM-Tg-rg-MP1833-Ab-2Anti-Rat ™EM30B monoclonal antibodyRat
GM-Tg-mg-MP1833-Ab-1/ GM-Tg-mg-MP1833-Ab-2Anti-Mouse ™EM30B monoclonal antibodyMouse
GM-Tg-cynog-MP1833-Ab-1/ GM-Tg-cynog-MP1833-Ab-2Anti-Cynomolgus/ Rhesus macaque ™EM30B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1833-Ab-1/ GM-Tg-felg-MP1833-Ab-2Anti-Feline ™EM30B monoclonal antibodyFeline
GM-Tg-cang-MP1833-Ab-1/ GM-Tg-cang-MP1833-Ab-2Anti-Canine ™EM30B monoclonal antibodyCanine
GM-Tg-bovg-MP1833-Ab-1/ GM-Tg-bovg-MP1833-Ab-2Anti-Bovine ™EM30B monoclonal antibodyBovine
GM-Tg-equg-MP1833-Ab-1/ GM-Tg-equg-MP1833-Ab-2Anti-Equine ™EM30B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1833-Ab-1/ GM-Tg-hg-MP1833-Ab-2; GM-Tg-rg-MP1833-Ab-1/ GM-Tg-rg-MP1833-Ab-2;
GM-Tg-mg-MP1833-Ab-1/ GM-Tg-mg-MP1833-Ab-2; GM-Tg-cynog-MP1833-Ab-1/ GM-Tg-cynog-MP1833-Ab-2;
GM-Tg-felg-MP1833-Ab-1/ GM-Tg-felg-MP1833-Ab-2; GM-Tg-cang-MP1833-Ab-1/ GM-Tg-cang-MP1833-Ab-2;
GM-Tg-bovg-MP1833-Ab-1/ GM-Tg-bovg-MP1833-Ab-2; GM-Tg-equg-MP1833-Ab-1/ GM-Tg-equg-MP1833-Ab-2
Products NameAnti-™EM30B monoclonal antibody
Formatmab
Target Name™EM30B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-™EM30B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CC50B/ ™EM30B/ CDC50B VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1833
    Target Name™EM30B
    Gene ID161291,238257,314224,719590,119872996,101082919,539324,100060966
    Gene Symbol and Synonyms9130011B11Rik,CDC50B,™EM30B
    Uniprot AccessionQ3MIR4
    Uniprot Entry NameCC50B_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseProstate Cancer
    Gene EnsemblENSG00000182107
    Target ClassificationN/A

    The target: ™EM30B, gene name: ™EM30B, also named as CDC50B. Enables aminophospholipid flippase activity. Involved in aminophospholipid transport and positive regulation of protein exit from endoplasmic reticulum. Predicted to be integral component of membrane. Predicted to be active in Golgi apparatus; endoplasmic reticulum; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.